Trevena, Inc. announced it is advancing TRV045 into clinical development, following receipt of a notification from the US FDA that the study may proceed.
[Trevena, Inc.]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Pancreatic Cell News Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
